Everest Medicines’ EVER001 shows promising Phase 1b/2a trial results for autoimmune kidney disease treatment
Everest Medicines has announced promising preliminary results from its ongoing Phase 1b/2a clinical trial of EVER001, a next-generation Bruton's tyrosine kinase (BTK) inhibitor, for the ... Read More
Everest Medicines launches clinical trial for personalized mRNA cancer vaccine EVM16
Everest Medicines Limited (HKEX: 1952.HK) has announced the launch of an Investigator-Initiated Clinical Trial (IIT) for its innovative personalized mRNA cancer vaccine, EVM16. The trial, ... Read More
Everest Medicines commissions mRNA vaccine production plant in Jiashan
Everest Medicines, a China-based biopharmaceutical company, has commenced operations at its mRNA vaccine production plant in Jiashan, Zhejiang Province, thereby becoming a fully-integrated biopharma. With ... Read More